AmDx PrognostX is working on development of a new clinical diagnostic test that would identify and stratify prediabetic patients at the highest risk of developing advanced diabetes-associated chronic diseases of the kidney, heart and brain. Through the firm's Diagnostics in Diabetes & Renal Health division, the firm is developing and commercializing a new test that is designed to predict rapidly-progressive diabetes in patients some considerable time before the person involved develops irreversible disease and diabetic kidney disease. The firm's simple blood-based diagnostic test serves to provide therapeutic options for those who are prediabetic or in early stage T2DM to prevent or delay rapid onset of progressive diabetic complications including CKD, CVD, CBVD, Diabetic Retinopathy, and/or T2DM-induced Dementia i.e., Alzheimers disease, Vascular dementia. It is estimated that 10-20% of all prediabetics or patients with early-stage T2DM are within this rapidly-progressive insidious disease stratum. However, there is currently no way for any patient to know whether or not they will rapidly progress into these serious irreversible diabetic-induced complications. The AmDx PrognostX plans would serve to make avialble such a test- potentially preventing onset of such diseases and/or related complications.
